All In Biotech

Drug Trial Radar · NCT05920135

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Sep 11, 2023

Primary completion

Aug 1, 2026

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Bridge Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center, Phase 1/2 study evaluating the safety, tolerability, PK, PD, and preliminary efficacy (antitumor activity) of BBT-207. It will consist of 3 parts; dose escalation, recommended phase 2 dose selection, and dose expansion.

Conditions

  • EGFR Mutant Advanced Non-Small Cell Lung Cancer

Interventions

  • BBT-207Drug

    BBT-207 given orally alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Phase 1a dose escalation] Determine Recommended Dose RangeTime frame: Approximately 12 months
  2. [Phase 1a dose escalation] Incidence of Treatment-Emergent Adverse Events, Adverse Events of Special Interest, Serious Adverse Events, and ≥grade 3 laboratory abnormalities.Time frame: Throughout study completion, approximately 12 months
  3. [Phase 1b Recommended Phase 2 Dose selection] Determine the RP2DTime frame: Approximately 12 months
  4. [Phase 2 dose expansion] Evaluate preliminary antitumor activityTime frame: Approximately 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.